479690-10-3

Basic information

• Product Name: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine
• Synonyms: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine
• CAS NO: 479690-10-3
• Molecular Formula: C₂₃H₂₆FN₃O₄
• Molecular Weight: 427.4686432
• Mol File: 479690-10-3.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 595.6±50.0 °C(Predicted)
• Appearance: /
• Density: 1.259±0.06 g/cm3(Predicted)
• PKA: 7.01±0.10(Predicted)
• CAS DataBase Reference: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine(479690-10-3)
• EPA Substance Registry System: 3-fluoro-{4-[(6-(Methyloxy)-7-{[3-(4-Morpholinyl)propyl]oxy}-4-quinolinyl)oxy]phenyl}aMine(479690-10-3)

Safety Data

• Hazardous Substances Data: 479690-10-3(Hazardous Substances Data)

Upstream product

• 75167-86-1 2-(benzyloxy)-1-methoxy-4-nitrobenzene 
• 205448-29-9 7-benzyloxy-4-hydroxy-6-methoxyquinoline 
• 636-93-1 5-nitroguaiacol 
• 7357-67-7 4-(3-chloropropyl)morpholine 
• 479690-24-9 4-(4-amino-2-fluorophenoxy)-6-methoxyquinolin-7-ol 
• 369-34-6 3,4-difluoronitrobenzene 
• 929252-63-1 hydrobromide salt of 4-(2-fluoro-4-nitrophenoxy)-6-methoxy-7-hydroxyquinoline 
• 4441-30-9 3-morpholin-4-ylpropan-1-ol 
• 479690-03-4 7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methyloxyquinoline 
• 286371-49-1 7-(benzyloxy)-4-chloro-6-methoxyquinoline 
• 1167053-13-5 6-methoxy-7-[3-(morpholin-4-yl)propoxy]-4(1H)-quinolinone 
• 1394166-09-6 7-(3-chloropropyloxy)-6-methoxy-4(1H)-quinolinone 
• 205448-31-3 4-chloro-6-methoxy-7-hydroxyquinoline 
• 1449763-02-3 1-(4-(3-chloropropoxy)-5-methoxy-2-nitrophenyl)-3-(dimethylamino)propyl-2-en-1-one 

Downstream Products

• 960299-46-1 methyl 1-(3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenyl)-2-oxo-1,2-dihydropyridine-3-carboxylate 
• 849217-64-7 foretinib 
• 849221-53-0 cyclopropane-1,1-dicarboxylic acid {3-fluoro-4-[6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinolin-4-ylamino]-phenyl}-amide (4-fluoro-phenyl)-amide 
• 1449763-30-7 phenyl 3-fluoro-4-(6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yloxy)phenylcarbamate 
• 1192300-38-1 N-{3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yloxy]phenyl}-2-trifluoromethylbenzenesulfonamide 

Relevant articles and documents

QUINOLINE OR QUINAZOLINE COMPOUND AND APPLICATION THEREOF

The present invention relates to quinoline or quinazoline compound represented by the formula (I), a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a prodrug molecule thereof, or a deuterated compound thereof. The compound of the presen

Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction

In our continuing efforts to develop novel c-Met inhibitors as potential anticancer candidates, a series of new N-sulfonylamidine derivatives were designed, synthesized via Cu-catalyzed multicomponent reaction (MCR) as the key step, and evaluated for their in vitro biological activities against c-Met kinase and four cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231). Most of the target compounds showed moderate to significant potency at both the enzyme-based and cell-based assay and possessed selectivity for A549 and HT-29 cancer cell lines. The preliminary SAR studies demonstrated that compound 26af (c-Met IC50 = 2.89 nM) was the most promising compound compared with the positive foretinib, which exhibited the remarkable antiproliferative activities, with IC50 values ranging from 0.28 to 0.72 μM. Mechanistic studies of 26af showed the anticancer activity was closely related to the blocking phosphorylation of c-Met, leading to cell cycle arresting at G2/M phase and apoptosis of A549 cells by a concentration-dependent manner. The promising compound 26af was further identified as a relatively selective inhibitor of c-Met kinase, which also possessed an acceptable safety profile and favorable pharmacokinetic properties in BALB/c mouse. The favorable drug-likeness of 26af suggested that N-sulfonylamidines may be used as a promising scaffold for antitumor drug development. Additionally, the docking study and molecular dynamics simulations of 26af revealed a common mode of interaction with the binding site of c-Met. These positive results indicated that compound 26af is a potential anti-cancer candidate for clinical trials, and deserves further development as a selective c-Met inhibitor.

Compound and application thereof in preparation of drugs for treating diseases caused by high expression of Flt3/c-Met kinase

The invention belongs to the technical field of chemical drug synthesis, and provides a compound and application thereof in preparation of drugs for treating diseases caused by high expression of Flt3/cMet kinase. The compound provided by the invention is prepared by amidation reaction of an intermediate A and an intermediate B. The compound provided by the invention has a strong effect of inhibiting Flt3/cMet kinase. The invention also discloses application of the compound and salt, solvate or prodrug thereof, or application of a pharmaceutical composition composed of one of the compound, salt, hydrate, solvate and prodrug thereof and an excipient in preparation of drugs for treating diseases caused by abnormal high expression of Flt3/cMet kinase, and application in drugs for treating and/or preventing proliferative diseases or cancers.